Subscribe to RSS
DOI: 10.1055/s-2005-922040
© Georg Thieme Verlag Stuttgart · New York
Therapie mit Wachstumshormon bei Erwachsenen mit nachgewiesenem Wachstumshormon-Mangel nach den Kriterien der evidenzbasierten Medizin
Treatment of proven growth hormone deficiency in adults with recombinant human growth hormone according to evidence-based criteriaPublication History
eingereicht: 28.3.2005
akzeptiert: 8.9.2005
Publication Date:
04 November 2005 (online)

Die Anwendung von rekombinantem humanem Wachstumshormon bei Erwachsenen mit ausreichend dokumentiertem Wachstumshormonmangel stellt mittlerweile eine verbreitete, akzeptierte Therapie mit einer hohen Effektivität und Sicherheit dar. Während die Wachstumshormontherapie bei hypophysär bedingt kleinwüchsigen Kindern bereits seit langem eine etablierte Therapieoption ist, haben zahlreiche Studien, insbesondere während des letzten Jahrzehnts gezeigt, dass die Therapie mit Wachstumshormon bei Erwachsenen mit nachgewiesenem Mangelzustand positive Auswirkungen auf die Knochengesundheit, kardiale Funktion, Körperzusammensetzung, Lebensqualität, zahlreiche metabolische Effekte und die Kognition hat. Für wachstumshormondefiziente Erwachsene konnte die Effektivität und Sicherheit einer Wachstumshormontherapie in zahlreichen randomisierten, kontrollierten Studien, Anwendungsbeobachtungen, systematischen Reviews und ökonomischen Analysen bewiesen werden. Dies ist jedoch bei Personen ohne nachgewiesenen Wachstumshormonmangel (z. B. Doping, Anti-Aging) nicht der Fall. Die hier durchgeführte Analyse vorwiegend randomisierter, kontrollierter, prospektiver Studien bezieht sich ausschließlich auf die Therapie Erwachsener mit nachgewiesenem Wachstumshormonmangel.
Ziel dieses Literaturreviews ist es, die Effektivität und Sicherheit der Therapie mit rekombinantem Wachstumhormon aufzuzeigen, wobei speziell auf die Zielkriterien der verbesserten Lebensqualität, des Knochenstoffwechsels, der kardialen Funktionen, der metabolischen Effekte und der kognitiven Funktionen fokussiert wird; dies vor dem Hintergrund, dass es sich bei der Therapie mit rekombinantem Wachstumshormon im Erwachsenenalter auch um eine vergleichsweise hochpreisige Therapie handelt.
Literatur
- 1
Ahmad A M, Guzder R, Wallace A M. et al .
Circadian and ultradian rhythm and leptin pulsatility in adult GH deficiency: effects
of GH replacement.
J Clin Endocrinol Metab.
2001;
86
3499-3506
MissingFormLabel
- 2
Baum H B, Biller B M, Finkelstein J S. et al .
Effects of physiologic growth hormone therapy on bone density and body composition
in patients with adult-onset growth hormone deficiency: a randomized, placebo-controlled
trial.
Ann Intern Med.
1996;
125
883-890
MissingFormLabel
- 3
Baum H B, Katznelson L, Sherman J C. et al .
Effects of physiological growth hormone (GH) therapy on cognition and quality of life
in patients with adult-onset GH deficiency.
J Clin Endocrinol Metab.
1998;
83
3184-3189
MissingFormLabel
- 4
Bell W, Davies J S, Evans W D. et al .
Somatic characteristics and cardiovascular risk factors in growth hormone deficiency:
A randomized, double-blind, placebo-controlled study of the effect of treatment with
recombinant human growth hormone.
Am J Hum Biol.
2004;
16
533-543
MissingFormLabel
- 5
Bengtsson B A, Eden S, Lonn L. et al .
Treatment of adults with growth hormone (GH) deficieny with recombinant human GH.
J Clin Endocrinol Metab.
1993;
76
309-317
MissingFormLabel
- 6
Beshyah S A, Shahi M, Skinner E. et al .
Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults.
Eur J Endocrinol.
1994;
130
451-458
MissingFormLabel
- 7
Bex M, Abs R, Maiter D. et al .
The effects of growth hormone replacement therapy on bone metabolism in adult-onset
growth hormone deficiency: a 2-year open randomized controlled multicenter trial.
J Bone Miner Res.
2002;
17
1081-1094
MissingFormLabel
- 8
Biller B M, Sesmilo G, Baum H B. et al .
Withdrawal of long-term physiological growth hormone (GH) administration: differential
effects on bone density and body composition in men with adult-onset GH deficiency.
J Clin Endocrinol Metab.
2000;
85
970-976
MissingFormLabel
- 9
Bryant J.
The clinical effectiveness and cost effectiveness of the use of human growth hormone
in adults.
Health Technol Assess.
2002;
6
1-106
MissingFormLabel
- 10
Bulow B, Ahren B, Erfurth E M.
Increased leptin and tumor necrosis factor ( per unit fat mass in hypopituitary women
without growth hormone treatment.
Eur J Endocrinol.
2001;
146
737-742
MissingFormLabel
- 11
Burman P, Broman J E, Hetta J. et al .
Quality of life in adults with growth hormone (GH) deficiency: response to treatment
with recombinant human GH in a placebo-controlled 21-month trial.
J Endocrinol Metab.
1995;
80
3585-3590
MissingFormLabel
- 12
Caidahl K, Eden S, Bengtsson B A.
Cardiovascular and renal effects of growth hormone.
Clin Endocrinol (Oxf).
1994;
40
393-400
MissingFormLabel
- 13
Carroll P V, Drake W M, Maher K T. et al .
Comparison of continuation or cessation of growth hormone (GH) therapy on body composition
and metabolic status in adolescents with severe GH deficiency at completion of linear
growth.
J Clin Endocrinol Metab.
2004;
89
3890-3895
MissingFormLabel
- 14
Chihara K, Koledova E, Shimatsu A. et al .
Adult GH deficiency in japanese patients: effects of GH treatment in a randomised,
placebo-controlled trial.
Eur J Endocrinol.
2004;
151
343-350
MissingFormLabel
- 15
Colao A, di Somma C, Cuocolo A. et al .
Improved cardiovascular risk factors and cardiac performance after 12 months of growth
hormone (GH) replacement in young adult patients with GH deficiency.
J Clin Endocrinol Metab.
2001;
86
1874-1881
MissingFormLabel
- 16
Davidson P, Milne R, Chase D. et al .
Growth hormone replacement in adults and bone mineral density: a systematic review
and meta-analysis.
Clin Endocrinol.
2004;
60
92-98
MissingFormLabel
- 17
Degerblad M, Almkvist O, Grunditz R. et al .
Physical and psychological capabilities during substitution therapy with recombinat
growth hormone in adults with growth hormone deficiency.
Acta Endocrinol.
1990;
123
185-193
MissingFormLabel
- 18
Deijen J B, de Boer H, Blok G J. et al .
Cognitive impairments and mood disturbances in growth hormone deficient men.
Psychoneuroendocrinology.
1996;
21
313-322
MissingFormLabel
- 19
De Novaes Soares C, Musolino N R, Neto M C. et al .
Impact of recombinat human growth hormone (RH-GH) treatment on psychatric, neuropsychological
and clinical profiles of GH deficient adults.
Arq Neuropsiquiatr.
1999;
57
182-189
MissingFormLabel
- 20
Elhadd T A, Abdu T A, Oxtoby J. et al .
Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism
and severe GH deficiency.
J Clin Endocrinol Metab.
2001;
86
4223-4232
MissingFormLabel
- 21
Ezzat S, Fear S, Gaillard R C. et al .
Gender-specific responses of lean body composition and non-gender-specific cardiac
function improvement after GH replacement in GH-deficient adults.
Horm Res.
2002;
11
273-281
MissingFormLabel
- 22
Fernholm R, Bramnert M, Hagg E. et al .
Growth hormone replacement therapy improves body composition and increases bone metabolism
in elderly patients with pituitary disease.
J Clin Endocrinol Metab.
2000;
85
4104-4112
MissingFormLabel
- 23
Finkenstedt G, Gasser R W, Hofle G. et al .
Effects of growth hormone (GH) replacement on bone metabolism and mineral density
in adult onset of GH deficiency: results of a double-blind placebo-controlled study
with open follow-up.
Eur J Endocrinol.
1997;
136
282-289
MissingFormLabel
- 24
Florkowski C M, Stevens S, Joyce P. et al .
Growth hormone replacement does not improve psychlogical well being in adult hypopituitarism:
a randomised cross over trial.
Psychoneuroendocrinology.
1998;
23
57-63
MissingFormLabel
- 25
Fort S, Weaver J, Monson J. et al .
The effects of low-dose recombinant human growth hormone on cardiovascular structure
and function in hypopituitarism growth hormone-deficient adults.
Endocrinol Metab.
1995;
2
119-126
MissingFormLabel
- 26
Gillberg P, Bramnert M, Thoren M. et al .
Commencing growth hormone replacement in adults with a fixed low dose: effects on
serum lipoproteins, glucose metabolism, body composition and cardiovascular function.
Growth Hormon IGF Res.
2001;
11
273-281
MissingFormLabel
- 27
Giusti M, Meineri I, Malagamba D. et al .
Impact of recombinant human growth hormone treatment on psychological profiles in
hypopituitary patients with adult-onset growth hormone deficiency.
Eur J Clin Invest.
1998;
28
13-19
MissingFormLabel
- 28
Gotherstrom G, Svensson J, Koranyi J. et al .
A prospective study of 5 years of GH replacement therapy in GH-deficient adults: Sustained
effects on body composition, bone mass and metabolic indices.
J Clin Endocrinol Metab.
2001;
86
4657-4665
MissingFormLabel
- 29
Hansen T B, Brixen K, Vahl N. et al .
Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium
homeostasis, and bone metabolism in adults with aquired GH deficiency: a double blind,
randomized, placebo-controlled study.
J Clin Endocrinol Metab.
1996;
81
3352-3359
MissingFormLabel
- 30
Herschbach P, Henrich G, Strasburger C J. et al .
Development and psychometric properties of a disease-specific quality of life questionnaire
for adult patients with growth hormone deficiency.
Eur J endocrinol.
2001;
145
255-265
MissingFormLabel
- 31
Hull K L, Harvey S.
Growth hormone therapy and qualitiy of life: possibilities, pitfalls and mechanisms.
J Endocrinol.
2003;
179
311-333
MissingFormLabel
- 32
Jadad A R, Moore R A, Carroll D. et al .
Assessing the quality of reports of randomized clinical trials: blinding necessary?.
Control Clin Trials.
1996;
17
1-12
MissingFormLabel
- 33
Kann P, Piepkorn B, Schehler B. et al .
Effect of long-term treatment with GH on bone metabolism, bone mineral density and
bone elasticity in GH-deficient adults.
Clin Endocrinol (Oxf).
1998;
48
561-568
MissingFormLabel
- 34
Kearney T, Navas de Gallegos C, Chrisoulidou A. et al .
Hypopituitarism is associated with triglyceride enrichment of very low-density lipoprotein.
J Clin Endocrinol Metab.
2001;
86
3900-3906
MissingFormLabel
- 35
Kreitschmann-Andermahr I, Hoff C, Saller B. et al .
Prevalence of pituitary deficiency in patients after aneurysmal subarachnoid hemorrhage.
J Clin Endocrinol Metab.
2004;
89
4986-4992
MissingFormLabel
- 36
Lehnert H.
Hormones and metabolism - exciting paths from biology to clinics.
Dtsch Med Wochenschr.
2005;
130
1573-1576
MissingFormLabel
- 37
Link K, Bulow B, Westman K. et al .
Low individualized growth hormone (GH) dose increased renal and cardiac growth in
young adults with childhood onset GH deficiency.
Clin Endocrinol (Oxf).
2001;
55
741-748
MissingFormLabel
- 38
Mahajan T, Crown A, Checkley S. et al .
Atypical depression in growth hormone deficient adults, and the beneficial effects
of growth hormone treatment on depression and quality of life.
Eur J Endocrinol.
2004;
151
325-332
MissingFormLabel
- 39
Maison P, Chanson P.
Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis.
Circulation.
2003;
108
2648-2652
MissingFormLabel
- 40
Marzullo P, Buckway C, Pratt K L. et al .
Leptin concentrations in GH deficiency: The effect of GH insensitivity.
J Clin endocrinol Metab.
2002;
87
540-545
MissingFormLabel
- 41
McGauley G A.
Qualtiy of life assessment before and after growth hormone treatment in adults with
growth hormone deficiency.
Acta Paediatr Scand Suppl.
1989;
356
70-72; discussion: 73 - 74
MissingFormLabel
- 42
Nass R, Huber R M, Klauss V. et al .
Effect of growth hormone (hGH) replacement therapy on physical work capacity and cardiac
and pulmonary function in patients with GH deficiency aquired in adulthood.
J Clin Endocrinol Metab.
1995;
80
552-557
MissingFormLabel
- 43
Nielsen S, Moller N, Christiansen J S. et al .
Pharmacological antilipolysis restores insulin sensitivity during growth hormone exposure.
Diabetes.
2001;
50
2301-2308
MissingFormLabel
- 44
Randeva H S, Murray R D, Lewandowski K C. et al .
Differential effects of GH replacement on the components of the leptin system in GH-deficient
individuals.
J Clin endocrinol Metab.
2002;
87
798-804
MissingFormLabel
- 45
Renehan A G, Zwahlen M, Minder C. et al .
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic
review and meta-regression analysis.
Lancet.
2004;
363
1346-1353
MissingFormLabel
- 46
Sackett D L, Rosenberg W M, Gray J A. et al .
Evidence based medicine: what it is and what it isnŽt.
BMJ.
1996;
312
71-72
MissingFormLabel
- 47
Schneider H J, Schneider M, von Rosen F. et al .
Hypophyseninsuffizienz nach Schädel-Hirn-Trauma.
Dtsch Arztebl.
2004;
101
A 712-717
MissingFormLabel
- 48
Smit J WA, Janssen Y JH, Lamb H J. et al .
Six months of recombinant human GH therapy in patients with ischemic heart failure
does not influence left ventricular function and mass.
J Clin endocrinol Metab.
2001;
86
4638-4643
MissingFormLabel
- 49
Sneppen S, Steensgaard-Hansen F, Feldt-Rasmussen U.
Cardiac effects of low-dose growth hormone replacement therapy in growth hormone-deficient
adults.
Horm Res.
2002;
58
21-28
MissingFormLabel
- 50 Society for Endocrinology .The use of growth hormone replacement in adult patients with severe growth hormone
deficiency. A position statement. Bristol, UK: Society for Endocrinology 2000
MissingFormLabel
- 51 Society for Endocrinology .Topical briefings: adult growth hormone replacement. Bristol, UK: Society for Endocrinology 2001
MissingFormLabel
- 52
Svensson J, Bengtsson B A, RosenT. et al .
Malignant disease and cardiovascular morbidity in hypopituitary adults with or without
growth hormone therapy.
J Clin Endocrinol Metab.
2004;
89
3309-3312
MissingFormLabel
- 53
Takala J, Ruokonen E, Webster N R. et al .
Increased mortality associated with growth hormone treatment in critically ill adults.
N Engl J Med.
1999;
341
785-792
MissingFormLabel
- 54
Thorner M O.
Critical evaluation of the safety of recombinant human growth hormone administration:
Statement from the Growth Hormone Research Society.
J Clin Endocrinol Metab.
2001;
86
1868-1870
MissingFormLabel
- 55
Thuesen L, Jorgensen J O, Muller J R. et al .
Short and long-term cardiovascular effects of growth hormone therapy in growth hormonedeficient
adults.
Clin Endocrinol (Oxf).
1994;
41
615-620
MissingFormLabel
- 56
Valcavi R, Gaddi O, Zini M. et al .
Cardiac performance and mass in adults with hypopituitarism: effects of one year of
growth hormone treatment.
J Clin Endocrinol Metab.
1995;
80
659-666
MissingFormLabel
- 57
Van der Lely A J.
Justified and unjustified use of growth hormone.
Postgrad Med J.
2004;
80
577-580
MissingFormLabel
- 58
Wallymahmed M E, Foy P, Shaw D. et al .
Quality of life, body composition and muscle strength in adult growth hormone deficiency:
the influence of growth hormone replacement therapy for up to 3 years.
Clin Endocrinol (Oxf).
1997;
47
439-446
MissingFormLabel
- 59
Weaver J U, Monson J P, Noonan K. et al .
The effect of low dose recombinant human growth hormone replacement on indices of
bone remodelling and bone mineral density in hypopituitary growth hormone-deficient
adults.
Endocrinol Metab.
1996;
3
(Suppl)
55-61
MissingFormLabel
- 60
Wilhelm B, Kann P.
Einfluss einer 7-jährigen Wachstumshormonsubstitution auf Knochenstoffwechsel, Knochendichte
und Knochenqualität bei Erwachsenen mit einem Wachstumshormonmangel.
Med Klin.
2004;
99
569-577
MissingFormLabel
9 (KIMS-Board: Unabhängiger wissenschaftlicher Beirat von KIMS (Pfizer International Metabolic Study). Auswertung und wissenschaftliche Aufarbeitung der im Zusammenhang mit der vom BfArM angeordneten Anwendungsbeobachtung generierten Daten in Deutschland.)
Priv.-Doz. Dr. med. Walter Josef Faßbender
Hospital zum Hl. Geist Kempen, Abteilung für Innere Medizin, Akademisches Lehrkrankenhaus
der Universität Düsseldorf
Von Broichhausen-Allee 1
47906 Kempen/Ndrh.
Phone: 02152/142381
Fax: 02152/142311
Email: w.j.fassbender@krankenhaus-kempen.de